CytoMed Therapeutics

27/05/2026

19/05/2026

🌟 Meet CytoMed Therapeutics & The Longevity Bank at IWE 2026! 🌟

We are excited to announce that CytoMed Therapeutics and The Longevity Bank will be participating in the International Wellness Expo 2026 at KLCC, Kuala Lumpur!

📍 Booth: 7E08
📅 Date: 20th – 22nd May 2026
⏰ Time: 9.00 AM – 6.00 PM

Join us to learn more about the future of cell therapy, regenerative medicine, and innovations shaping the healthcare landscape. Our team will be there to share insights on our work, answer your questions, and connect with fellow innovators, healthcare enthusiasts, and members of the public.

Whether you are curious about advanced therapeutics, healthy longevity, or the future of biotechnology, we would love to meet you!

See you at KLCC! 👋

13/05/2026

🔬 What Does Japan’s iPSC Approval Mean for the Future of Cell Therapy?

Japan has approved a new iPSC-based therapy, marking a major step forward for regenerative medicine and bringing platforms like Cynata’s into focus.

👉 https://www.theaustralian.com.au/business/stockhead/content/japans-milestone-ipsc-approval-puts-cynatas-platform-in-spotlight/news-story/2006b8a1cf7763a91643a03160c667da

So what exactly are iPSCs?

Induced pluripotent stem cells (iPSCs) are adult cells that have been reprogrammed back into a stem cell-like state. This means they can be turned into many different types of cells in the body, from immune cells to tissue-specific cells.

What makes them particularly exciting:

They can be expanded from a single source, enabling large-scale, consistent manufacturing
They reduce reliance on donor variability, improving reproducibility across treatments
They support the development of off-the-shelf therapies that can be stored and used when needed

This approval is more than just a regulatory milestone. It reflects growing confidence in iPSC-based platforms and signals a broader shift toward scalable, standardised cell therapies.

For companies like CytoMed Therapeutics, this trend is highly relevant. As the industry moves beyond patient-specific approaches, allogeneic strategies and GMP-ready manufacturing will be key to making advanced therapies more accessible.

iPSC technologies, alongside immune cell platforms like γδ T cells, are helping shape a future where cell therapy is not just effective, but also scalable and widely available.

15/04/2026

🔬 CAR-T Therapy Is Expanding Beyond Cancer — And That’s a Big Deal

CAR-T therapy has already transformed the treatment of certain blood cancers. Now, new research highlighted in Nature shows it may also be used to treat autoimmune diseases, where the immune system mistakenly attacks the body.

👉 https://www.nature.com/articles/d41586-026-01108-4

This highlights the expanding potential of engineered immune cell therapies. As the science evolves, scalable and off-the-shelf approaches could play a key role in bringing these breakthroughs to more patients worldwide.

Fourteen months after treatment with engineered immune cells, the recipient has no symptoms and doesn’t need to take medication.

01/04/2026

🔬 What is CAR-NKT Cell Therapy and Why Is It Exciting?

A recent study is highlighting a new type of immunotherapy called CAR-NKT cell therapy, showing strong potential against difficult cancers like endometrial carcinoma.

👉 https://www.oncology-central.com/car-nkt-cell-therapy-offers-scalable-off-the-shelf-immunotherapy-for-endometrial-carcinoma/

So what exactly is CAR-NKT?

CAR-NKT cells are a special type of immune cell that combine the strengths of both T cells and natural killer (NK) cells. Scientists engineer these cells with a “CAR” (chimeric antigen receptor), allowing them to recognise and attack cancer cells more precisely.

What makes them particularly interesting is how they work:

- They can attack cancer through multiple pathways at once, making it harder for tumors to escape treatment
- They can be produced from donor cells and stored, creating a ready-to-use, off-the-shelf therapy

This is part of a bigger shift in cell therapy, moving toward treatments that are not only powerful, but also scalable and accessible.

This reinforces the growing importance of allogeneic (donor-derived) immune cell therapies. As the field evolves beyond traditional CAR-T, platforms that are off-the-shelf and adaptable are becoming increasingly relevant in shaping the future of cancer treatment.

-NKT

New research describes how CAR-NKT cell therapy is more effective than current immunotherapies at fighting endometrial cancer.

21/03/2026

Selamat Hari Raya Puasa from all of us at CytoMed Therapeutics 🌙✨

May this festive season bring you and your loved ones joy, peace, and renewed blessings. As we celebrate togetherness and gratitude, we also thank you for being part of our journey.

Wishing you a warm and meaningful Hari Raya. 💚

11/03/2026

Big Pharma Doubles Down on Next-Gen CAR-T with Gilead’s Acquisition of Arcellx

Gilead Sciences is acquiring Arcellx for up to $7.8 billion, signaling a major commitment to next-generation CAR-T therapy. This deal reflects how large biopharma players are increasingly betting on innovative cell therapies that go beyond traditional approaches and aim to improve safety, scalability, and effectiveness in cancer treatment.

🔗 https://nai500.com/blog/2026/02/gilead-to-acquire-arcellx-for-up-to-7-8-billion-doubling-down-on-next-generation-car-t-therapy/?utm_source=chatgpt.com

For the broader cell therapy industry, this acquisition reinforces confidence that advanced immune cell therapies — especially allogeneic and engineered platforms — are entering a new phase of commercial relevance.

As innovators in allogeneic γδ T-cell therapy, market validation like this underscores the growing importance of scalable, off-the-shelf immunotherapies. It shows that not only scientific progress but also strategic investment is shifting toward next-generation modalities that could benefit patients with unmet needs.

-T

Gilead Sciences (Nasdaq: GILD) announced on Monday an agreement to acquire its cancer immunotherapy partner Arcellx (Nasdaq: ACLX) for up to $7.8 billion, securing full control of anito-cel…

27/02/2026

📈 CytoMed in the Spotlight Alongside Other Emerging Biotech Stocks

A recent article from Yahoo Finance highlighted CytoMed Therapeutics alongside other promising small-cap biotech stocks that investors and industry watchers are keeping an eye on. These companies are gaining attention not just for their share price moves, but because they’re operating in high-growth areas of biotech and immunotherapy where scientific advances and clinical progress can drive long-term value.

For CytoMed, this kind of market recognition reflects growing interest in the potential of allogeneic immune cell therapies. In a landscape where personalized and off-the-shelf cellular immunotherapies are becoming increasingly important, CytoMed’s work in developing scalable γδ T-cell platforms positions it as a player to watch as the field evolves.

🚀 What makes this exciting?
• CytoMed’s focus on scalable, next-generation cell therapy aligns with broader industry trends.
• As science and manufacturing capabilities improve, allogeneic approaches offer the potential for more accessible, off-the-shelf treatments.
• Continued investor interest suggests confidence in the long-term opportunity for novel immunotherapies that address unmet medical needs.

Read the full article here:
🔗 https://uk.finance.yahoo.com/news/cytomed-therapeutics-2-more-penny-180526792.html

As February begins, major U.S. stock indexes have shown a robust start, with the Dow Jones Industrial Average and S&P 500 posting significant gains. In such an optimistic market climate, investors often look beyond the well-known giants to explore opportunities in lesser-known areas like penny stock...

11/02/2026

Why China’s New Drug Innovation Rules Matter for Global Biotech and for CytoMed

China has fundamentally rewritten how innovative medicines are reviewed and approved by embedding fast-track pathways into law. Thanks to these reforms, approval times have dropped dramatically and China approved more new medicines in 2024 than the U.S. FDA, creating a more predictable and innovation-friendly environment. You can read more here:
🔗 https://www.businesstimes.com.sg/opinion-features/how-china-rewrote-rules-drug-innovation

For biotech companies like CytoMed Therapeutics, this shift presents a unique opportunity. A faster regulatory process means innovative therapies including allogeneic cell therapies, gets to patients more quickly with clearer development pathways and greater collaboration potential.

China’s growing market, regulatory momentum, and scientific ecosystem align with CytoMed’s mission to bring accessible, next-generation cell therapies to a broader patient population. Expanding into China isn’t just about scale. It’s about being part of a market that’s rapidly becoming a global innovation hub for advanced medicine.

In an era where AI-driven drug discovery accelerates candidate generation faster than traditional systems can evaluate them, regulatory velocity becomes a binding constraint Read more at The Business Times.